DE3587806T2 - Tricyclische Verbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzung. - Google Patents

Tricyclische Verbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzung.

Info

Publication number
DE3587806T2
DE3587806T2 DE3587806T DE3587806T DE3587806T2 DE 3587806 T2 DE3587806 T2 DE 3587806T2 DE 3587806 T DE3587806 T DE 3587806T DE 3587806 T DE3587806 T DE 3587806T DE 3587806 T2 DE3587806 T2 DE 3587806T2
Authority
DE
Germany
Prior art keywords
hydroxy
substance
formula
compound
allyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3587806T
Other languages
German (de)
English (en)
Other versions
DE3587806D1 (de
Inventor
Toshio Goto
Hiroshi Hatanaka
Tohru Kino
Masakuni Okuhara
Hirokazu Tanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB848430455A external-priority patent/GB8430455D0/en
Priority claimed from GB858502869A external-priority patent/GB8502869D0/en
Priority claimed from GB858508420A external-priority patent/GB8508420D0/en
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE3587806D1 publication Critical patent/DE3587806D1/de
Publication of DE3587806T2 publication Critical patent/DE3587806T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces
    • C12R2001/55—Streptomyces hygroscopicus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/886—Streptomyces
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/886—Streptomyces
    • Y10S435/898—Streptomyces hygroscopicus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE3587806T 1984-12-03 1985-11-30 Tricyclische Verbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzung. Expired - Lifetime DE3587806T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB848430455A GB8430455D0 (en) 1984-12-03 1984-12-03 Fr-900506 substance
GB858502869A GB8502869D0 (en) 1985-02-05 1985-02-05 Ws 7238 substances
GB858508420A GB8508420D0 (en) 1985-04-01 1985-04-01 Fr-900506 & fr-900525 substances

Publications (2)

Publication Number Publication Date
DE3587806D1 DE3587806D1 (de) 1994-06-01
DE3587806T2 true DE3587806T2 (de) 1994-08-25

Family

ID=27262535

Family Applications (2)

Application Number Title Priority Date Filing Date
DE3587806T Expired - Lifetime DE3587806T2 (de) 1984-12-03 1985-11-30 Tricyclische Verbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzung.
DE1995175026 Active DE19575026I2 (de) 1984-12-03 1985-11-30 Tricyclische Verbindungen Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE1995175026 Active DE19575026I2 (de) 1984-12-03 1985-11-30 Tricyclische Verbindungen Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzung

Country Status (24)

Country Link
US (15) US4894366A (enExample)
EP (1) EP0184162B1 (enExample)
JP (6) JPH0372483A (enExample)
KR (5) KR930010704B1 (enExample)
CN (1) CN1013687B (enExample)
AT (1) ATE104984T1 (enExample)
AU (1) AU592067B2 (enExample)
CA (1) CA1338491C (enExample)
CY (1) CY1912A (enExample)
DE (2) DE3587806T2 (enExample)
DK (1) DK169550B1 (enExample)
ES (1) ES8705038A1 (enExample)
FI (2) FI87803C (enExample)
GR (1) GR852904B (enExample)
HK (1) HK18596A (enExample)
HU (1) HU195250B (enExample)
IE (1) IE62865B1 (enExample)
IL (2) IL92345A (enExample)
LU (1) LU90317I2 (enExample)
MX (1) MX9202943A (enExample)
NL (1) NL960023I2 (enExample)
NO (1) NO168372C (enExample)
NZ (1) NZ214407A (enExample)
PT (1) PT81589B (enExample)

Families Citing this family (317)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5254562A (en) * 1984-12-03 1993-10-19 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5266692A (en) * 1984-12-03 1993-11-30 Fujisawa Pharmaceutical Co., Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
DE3886265T2 (de) * 1987-06-05 1994-04-28 Fujisawa Pharmaceutical Co Anti-FR-900506-Stoffe-Antikörper und höchstempfindliches Enzym-Immunoassay-Verfahren.
DE3737523A1 (de) * 1987-11-05 1989-05-18 Bayer Ag Verwendung von substituierten hydroxypiperidinen als antivirale mittel
DE3844904C2 (de) * 1987-11-09 1997-01-30 Sandoz Ag Neue Verwendung von 11,28-Dioxa-4-azatricyclo-[22.3.1.0·4·,·9·]octacos-18-en-Derivaten
AT400808B (de) * 1987-11-09 1996-03-25 Sandoz Ag Verwendung von tricyclischen verbindungen zur herstellung von topischen arzneimitteln
DE3838035C2 (de) * 1987-11-09 1994-03-24 Sandoz Ag Neue Verwendung von 11,28-dioxa-4-azatricyclo[22.3.1.O·4··,··9·]octacos-18-en-Derivaten
DK175235B1 (da) * 1987-11-09 2004-07-19 Novartis Ag Ny anvendelse af azatricycloderivater og farmaceutiske præparater med indhold deraf
US5366971A (en) * 1987-11-09 1994-11-22 Sandoz Ltd. Use of 11,28-dioxa-4-azatricyclo[22.3.1.04,9 ]octacos-18-ene derivatives and pharmaceutical compositions containing them
WO1989005304A1 (en) * 1987-12-09 1989-06-15 Fisons Plc Macrocyclic compounds
GB8728820D0 (en) * 1987-12-09 1988-01-27 Fisons Plc Compounds
AT407957B (de) * 1987-12-17 2001-07-25 Novartis Erfind Verwalt Gmbh Neue verwendung von 11,28-dioxa-4-azatricyclo- (22.3.1.04,9)octacos-18-en-derivaten und sie enthaltende pharmazeutische zubereitungen
EP0323865A1 (en) * 1988-01-07 1989-07-12 Merck & Co. Inc. Novel immunosuppressant agent
US4981792A (en) * 1988-06-29 1991-01-01 Merck & Co., Inc. Immunosuppressant compound
DE68921934T2 (de) * 1988-06-29 1995-10-19 Merck & Co Inc Immunsuppressives Agens.
US5290772A (en) * 1988-06-29 1994-03-01 Merck & Co., Inc. Immunosuppressant agent
ATE131536T1 (de) * 1988-08-01 1995-12-15 Fujisawa Pharmaceutical Co Fr-901154- und fr-901155-derivate, verfahren zu ihrer herstellung
US5202258A (en) * 1988-08-05 1993-04-13 Merck & Co., Inc. Immunosuppressant-producing culture
EP0356399A3 (en) * 1988-08-26 1991-03-20 Sandoz Ag Substituted 4-azatricyclo (22.3.1.04.9) octacos-18-ene derivatives, their preparation and pharmaceutical compositions containing them
EP0358508A3 (en) * 1988-09-08 1991-03-20 Merck & Co. Inc. Novel immunosuppressant compound
CA1316916C (en) * 1988-10-12 1993-04-27 David Askin Hydroxide mediated fk-506 rearrangement product
DE68904037T2 (de) * 1988-10-12 1993-06-03 Merck & Co Inc Verfahren zur umlagerung von fk-506 unter beteiligung von hydroxid.
US4980466A (en) * 1988-10-12 1990-12-25 Merck & Co., Inc. Hydroxide mediated FK-506 rearrangement product
GB2225576B (en) * 1988-11-29 1992-07-01 Sandoz Ltd Substituted azatricyclo derivatives and metabolites,their preparation and pharmaceutical compositions containing them
EP0378317A3 (en) * 1989-01-13 1990-11-28 Merck & Co. Inc. Microbial transformation product of l-679,934
EP0378320A3 (en) * 1989-01-13 1990-11-28 Merck & Co. Inc. Microbial transformation product
US5268370A (en) * 1989-01-13 1993-12-07 Merck & Co., Inc. Microbial transformation product of L-679,934
US4975372A (en) * 1989-01-13 1990-12-04 Merck & Co., Inc. Microbial transformation product of L-683,590
US5272068A (en) * 1989-03-15 1993-12-21 Merck & Co., Inc. Process for producing immunosuppressant agent L-683942 by fermentation
DE69015393T2 (de) * 1989-03-15 1995-06-01 Merck & Co Inc Immunosuppressives Mittel.
EP0388152B1 (en) * 1989-03-15 1994-10-12 Merck & Co. Inc. Process for producing an immunosuppressant agent (demethimmunomycin) using a mutant strain of a microorganism
US5155228A (en) * 1989-03-23 1992-10-13 Merck & Co., Inc. FK-506 C10-C18 process intermediates
US4940797A (en) * 1989-03-23 1990-07-10 Merck & Co., Inc. Process for synthesis of FK-506 C10-C18 intermediates
US5068323A (en) * 1989-04-21 1991-11-26 Merck & Co., Inc. Thermally re-arranged FK-506 derivatives having immunosuppressant activity
EP0399579A1 (en) * 1989-04-21 1990-11-28 Merck & Co. Inc. Macrolides having immunosuppressive activity
US5057608A (en) * 1989-04-21 1991-10-15 Merck & Co., Inc. Immunoregulants, immunosuppressants, process to make ring expanded macrolide related to FK-506/FK-520
US5270187A (en) * 1989-05-05 1993-12-14 Merck & Co., Inc. Microbial transformation product
US4987139A (en) * 1989-05-05 1991-01-22 Merck & Co., Inc. FK-520 microbial transformation product
JPH0368583A (ja) * 1989-05-05 1991-03-25 Merck & Co Inc 新規微生物変換物質
IE64214B1 (en) * 1989-06-06 1995-07-26 Fujisawa Pharmaceutical Co Macrolides for the treatment of reversible obstructive airways diseases
CA2018710A1 (en) * 1989-06-13 1990-12-13 Shieh-Shung T. Chen L-683,590 microbial transformation product
US5138052A (en) * 1989-06-13 1992-08-11 Merck & Co., Inc. L-683,590 microbial transformation product
KR920700212A (ko) * 1989-06-14 1992-02-19 쟝 크라머·한스 루돌프 하우스 헤테로원자-함유 트리사이클릭 화합물
US5235066A (en) * 1989-06-30 1993-08-10 Merck & Co., Inc. FK-506 type macrolide intermediate
US5164525A (en) * 1989-06-30 1992-11-17 Merck & Co., Inc. Synthetic process for fk-506 type macrolide intermediates
EP0413532A3 (en) * 1989-08-18 1991-05-15 Fisons Plc Macrocyclic compounds
WO1991002736A1 (en) * 1989-08-18 1991-03-07 Fisons Plc Macrocyclic compounds
US5011943A (en) * 1989-08-28 1991-04-30 Merck Frosst Canada, Inc. FK-506 C10 -C24 process intermediates
GR1001225B (el) * 1989-09-14 1993-06-30 Fisons Plc Νέαι μακροκυκλικαί ενώσεις και νέα μέ?οδος χρήσεως τους.
US5215995A (en) * 1989-10-16 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Hair revitalizing agent
DK0427680T3 (da) * 1989-11-09 1995-12-18 Sandoz Ltd Heteroatom-holdige cykliske forbindelser
US5208228A (en) * 1989-11-13 1993-05-04 Merck & Co., Inc. Aminomacrolides and derivatives having immunosuppressive activity
IE904050A1 (en) * 1989-11-13 1991-05-22 Merck & Co Inc Aminomacrolides and derivatives having immunosuppressive¹activity
GB8925797D0 (en) * 1989-11-15 1990-01-04 Fisons Plc Compositions
EP0444829A3 (en) * 1990-02-27 1992-06-03 Fisons Plc Immunosuppressive compounds
US5260301A (en) * 1990-03-01 1993-11-09 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical solution containing FK-506
US5064835A (en) * 1990-03-01 1991-11-12 Merck & Co., Inc. Hydroxymacrolide derivatives having immunosuppressive activity
WO1991013899A1 (en) * 1990-03-12 1991-09-19 Fujisawa Pharmaceutical Co., Ltd. Tricyclo compounds
EP0594600A1 (en) * 1990-03-13 1994-05-04 FISONS plc Immunosuppressive macrocyclic compounds
US5296489A (en) * 1990-03-13 1994-03-22 Fisons Immunosuppressive macrocyclic compounds
EP0455427A1 (en) * 1990-04-30 1991-11-06 Merck & Co. Inc. Deoxymacrolide derivatives having immunosuppressive activity
WO1991017754A1 (en) * 1990-05-11 1991-11-28 Fujisawa Pharmaceutical Co., Ltd. Methods for treating and preventing inflammation of mucosa and blood vessels using fk 506 and related compounds
JPH05507915A (ja) * 1990-06-11 1993-11-11 藤沢薬品工業株式会社 特発性血小板減少性紫斑病およびバセドウ病治療薬製造のためのｆｋ５０６等のマクロライド化合物の用途
US5643901A (en) * 1990-06-11 1997-07-01 Fujisawa Pharmaceutical Co., Ltd. Medicament for treating idiopathic thrombocytopenic purpura
GB9014136D0 (en) * 1990-06-25 1990-08-15 Fujisawa Pharmaceutical Co Tricyclo compounds,a process for their production and a pharmaceutical composition containing the same
CA2044846A1 (en) * 1990-06-25 1991-12-26 Thomas R. Beattie Antagonists of immunosuppressive macrolides
US5210030A (en) * 1990-06-25 1993-05-11 Merck & Co., Inc. Process for selectively acylating immunomycin
US5342935A (en) * 1990-06-25 1994-08-30 Merck & Co., Inc. Antagonists of immunosuppressive macrolides
US5190950A (en) * 1990-06-25 1993-03-02 Merck & Co., Inc. Antagonists of immunosuppressive macrolides
GB9014681D0 (en) * 1990-07-02 1990-08-22 Fujisawa Pharmaceutical Co Tricyclo compounds,a process for their production and a pharmaceutical composition containing the same
MY110418A (en) * 1990-07-02 1998-05-30 Novartis Ag Heteroatoms-containing tricyclic compounds.
EP0466365A3 (en) * 1990-07-03 1992-04-15 Merck & Co. Inc. Novel immunosuppressant fermentation products of a microorganism
GB2245891A (en) * 1990-07-09 1992-01-15 Fujisawa Pharmaceutical Co Tricyclo compounds
GB2246350A (en) * 1990-07-23 1992-01-29 Fujisawa Pharmaceutical Co Tricyclo compounds
US5089517A (en) * 1990-08-03 1992-02-18 The Board Of Trustees Of The Leland Stanford Junior University Neuroprotection by indolactam v and derivatives thereof
JPH06500102A (ja) * 1990-08-18 1994-01-06 フアイソンズ・ピーエルシー マクロ環状化合物
GB2247620A (en) * 1990-09-07 1992-03-11 Fujisawa Pharmaceutical Co The use of macrolide compounds for cytomegalovirus infection
CA2051872A1 (en) * 1990-09-24 1992-03-25 Kevin M. Byrne Directed biosynthesis process for prolyl-immunomycin
GB2248184A (en) * 1990-09-28 1992-04-01 Fujisawa Pharmaceutical Co New use of macrolide compounds for active oxygen-mediated diseases
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
US5233036A (en) * 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5348966A (en) * 1990-10-24 1994-09-20 Fujisawa Pharmaceutical Co., Ltd. Method for treating pyoderma and Sezary's syndrome using FK 506 and related compounds
CA2054128A1 (en) * 1990-10-29 1992-04-30 Kevin M. Byrne Process for the production of analogues of immunomycin
PH31204A (en) * 1990-11-02 1998-05-05 Fujisawa Pharmaceutical Co Pharmaceutical composition.
CA2054983A1 (en) * 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
GB2249787A (en) * 1990-11-19 1992-05-20 Fujisawa Pharmaceutical Co Lactone compounds
GB9027471D0 (en) * 1990-12-19 1991-02-06 Fujisawa Pharmaceutical Co Novel compound
US5194378A (en) * 1991-01-28 1993-03-16 Merck & Co., Inc. Process for producing fk-506
US5116756A (en) * 1991-01-28 1992-05-26 Merck & Co., Inc. Process for producing FK-506
WO1992013862A1 (en) * 1991-02-05 1992-08-20 Fujisawa Pharmaceutical Co., Ltd. Lactone compounds
US5147877A (en) * 1991-04-18 1992-09-15 Merck & Co. Inc. Semi-synthetic immunosuppressive macrolides
DE69231644T2 (de) * 1991-04-26 2001-05-23 Fujisawa Pharmaceutical Co., Ltd. Verwendung von makrolid-verbindungen gegen augenerkrankungen
US5162334A (en) * 1991-05-13 1992-11-10 Merck & Co., Inc. Amino O-alkyl, O-alkenyl and O-alkynlmacrolides having immunosuppressive activity
US5262533A (en) * 1991-05-13 1993-11-16 Merck & Co., Inc. Amino O-aryl macrolides having immunosuppressive activity
US5565560A (en) * 1991-05-13 1996-10-15 Merck & Co., Inc. O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5250678A (en) 1991-05-13 1993-10-05 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
EP0528452A1 (en) * 1991-06-19 1993-02-24 Merck & Co. Inc. Immunomycin enzymatic and/or microbial methylation products
US5225403A (en) * 1991-06-25 1993-07-06 Merck & Co., Inc. C-21 hydroxylated FK-506 antagonist
US5149701A (en) * 1991-08-01 1992-09-22 Merck & Co., Inc. C-31 methylated FR-900520 cyclic hemiketal immunosuppressant agents
US5198358A (en) * 1991-08-28 1993-03-30 Merck & Co., Inc. Microorganism for producing C-31 desmethyl FR-900520 cyclic hemiketal immunosuppressant agent
US5273979A (en) * 1991-08-01 1993-12-28 Merck & Co., Inc. C-31 desmethyl FR-900520 cyclic hemiketal immunosuppressant agent
US5189042A (en) * 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
US5708002A (en) * 1991-09-05 1998-01-13 Abbott Laboratories Macrocyclic immunomodulators
ES2179823T3 (es) * 1991-09-05 2003-02-01 Abbott Lab Inmunosupresor macrolido.
ZA926812B (en) 1991-09-09 1993-04-28 Merck & Co Inc O-heteroaryl,o-alkylheteroaryl,o-alkenylheteroaryl and o-alkynylheteroaryl macrolides having immunosupressive activity
US5252732A (en) * 1991-09-09 1993-10-12 Merck & Co., Inc. D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity
US5247076A (en) * 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
US5208241A (en) * 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
US5164495A (en) * 1991-09-18 1992-11-17 Abbott Laboratories Method for preparing a dicarboxylic acid half-acid ester of FK506
US5221625A (en) * 1992-01-10 1993-06-22 Merck & Co., Inc. Cyclcic FR-900520 microbial biotransformation agent
EP0624093A1 (en) * 1992-01-28 1994-11-17 KARPAS, Abraham The use of a compound for the manufacture of a medicament for the treatment of hiv infection
JP3140228B2 (ja) * 1992-02-17 2001-03-05 ファイザー製薬株式会社 新規な大環状ラクトンおよびその生産菌
WO1993018042A1 (en) * 1992-03-02 1993-09-16 Pfizer Inc. Desosamino derivatives of macrolides as immunosuppressants and antifungal agents
ES2102642T3 (es) * 1992-03-02 1997-08-01 Pfizer Derivados azucares de macrolidos.
CA2131373C (en) * 1992-03-02 1999-01-26 Kevin Koch 2-aminosugar derivatives of macrolides
WO1993018049A1 (en) * 1992-03-02 1993-09-16 Pfizer Inc. Fluorosugar derivatives of macrolides
ATE138807T1 (de) 1992-03-27 1996-06-15 American Home Prod 29-demethoxyrapamycin zur induktion der immunosuppression
CA2091194A1 (en) * 1992-04-08 1993-10-09 Richard D. Connell 2-oxo-ethyl derivatives as immunosuppressants
HUT66531A (en) * 1992-05-07 1994-12-28 Sandoz Ag Heteroatoms-containing tricyclic compounds, pharmaceutical prepns contg. them and process for producing them
WO1993025533A1 (en) * 1992-06-05 1993-12-23 Abbott Laboratories Methods and reagents for the determination of immunosuppressive agents
US5284877A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkyl and alkenyl macrolides having immunosuppressive activity
US5284840A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkylidene macrolides having immunosuppressive activity
US5264355A (en) * 1992-07-02 1993-11-23 Merck & Co., Inc. Methlating enzyme from streptomyces MA6858
ZA935112B (en) * 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5324644A (en) * 1992-07-28 1994-06-28 Merck & Co., Inc. Process for producing immunosuppressant agent
ATE213272T1 (de) * 1992-08-12 2002-02-15 Fujisawa Pharmaceutical Co Monoklonaler antikörper spezifisch für das fk-506-bindende protein, methode zur bestimmung des gehaltes an fk-506-bindendem protein in einer probe und reagenzsatz dafür
US5365948A (en) * 1992-08-21 1994-11-22 J & W Mcmichael Software Inc. Method for use in treating a patient with FK 506 to prevent an adverse immune response
US5268282A (en) * 1992-09-28 1993-12-07 Merck & Co., Inc. Cyclic FR-900520 microbial biotransformation agent
US5290689A (en) * 1992-09-28 1994-03-01 Merck & Co., Inc. New cyclic FR-900520 microbial biotransformation agent
US5283183A (en) * 1992-09-28 1994-02-01 Merck & Co., Inc. Cyclic FR-900520 microbial biotransformation agent
US5268281A (en) * 1992-09-28 1993-12-07 Merck & Co., Inc. Cyclic FR-900520 microbial biotransformation agent
US5318895A (en) * 1992-10-05 1994-06-07 Merck & Co., Inc. Aspergillus niger mutants
GB9227055D0 (en) * 1992-12-29 1993-02-24 Fujisawa Pharmaceutical Co New use
DE4300478C2 (de) * 1993-01-11 1998-05-20 Eos Electro Optical Syst Verfahren und Vorrichtung zum Herstellen eines dreidimensionalen Objekts
JPH08507788A (ja) * 1993-03-17 1996-08-20 アボツト・ラボラトリーズ 置換脂環式アミン含有大環状免疫調節剤
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
AT408520B (de) * 1993-05-27 2001-12-27 Novartis Erfind Verwalt Gmbh Galenische formulierungen
MY110603A (en) * 1993-05-27 1998-08-29 Novartis Ag Tetrahydropyran derivatives
GB2279006A (en) * 1993-06-03 1994-12-21 Fujisawa Pharmaceutical Co Treatment of amyotrophic lateral sclerosis
JPH06345646A (ja) * 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
US5352783A (en) * 1993-06-09 1994-10-04 Merck & Co., Inc. Microbial transformation product having immunosuppressive activity
US5359060A (en) * 1993-07-06 1994-10-25 Pfizer, Inc. Phosponated derivatives of macrolides
EP0711298A1 (en) * 1993-07-30 1996-05-15 Abbott Laboratories Activated macrolactams having immunomodulatory activities
GB2281294A (en) * 1993-08-23 1995-03-01 Fujisawa Pharmaceutical Co Process for producing half esters of the macrolide FK506
US5616588A (en) 1993-09-30 1997-04-01 American Home Products Corporation Rapamycin formulation for IV injection
UA41884C2 (uk) * 1993-11-05 2001-10-15 Амерікан Хоум Продактс Корпорейшн Спосіб відокремлення рапаміцину від кислотних, основних та неполярних нейтральних домішок, присутніх в концентраті екстрактів ферментаційного бульйону або маточних розчинів
US5898029A (en) * 1994-04-12 1999-04-27 The John Hopkins University Direct influences on nerve growth of agents that interact with immunophilins in combination with neurotrophic factors
US5880280A (en) * 1994-06-15 1999-03-09 Merck & Co., Inc. Aryl, alkyl, alkenyl and alkynylmacrolides having immunosuppressive activity
US5693648A (en) * 1994-09-30 1997-12-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity
CN100335063C (zh) 1994-10-26 2007-09-05 诺瓦蒂斯有限公司 药物组合物
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
US5616595A (en) * 1995-06-07 1997-04-01 Abbott Laboratories Process for recovering water insoluble compounds from a fermentation broth
CN1137680C (zh) * 1995-09-19 2004-02-11 藤泽药品工业株式会社 气雾剂组合物
PT956034E (pt) 1996-07-30 2002-12-31 Novartis Ag Composicoes farmaceuticas para o tratamento da rejeicao de transplantes estados inflamatorios ou auto-imunes compreendendo ciclosporina a e 40-o-(2-hidroxietil)-rapamicina
KR100244164B1 (ko) * 1997-07-15 2000-03-02 김용옥 수용성 고분자-타크로리무스 접합체 화합물 및 그의 제조 방법
US6562620B2 (en) * 1997-09-19 2003-05-13 Mcgill University Medium to promote islet cell survival
US6015815A (en) * 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US7399480B2 (en) 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US20030129215A1 (en) 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US8057816B2 (en) 1997-09-26 2011-11-15 Abbott Laboratories Compositions and methods of administering paclitaxel with other drugs using medical devices
US7357942B2 (en) 1997-09-26 2008-04-15 Abbott Laboratories Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
US8394398B2 (en) 1997-09-26 2013-03-12 Abbott Laboratories Methods of administering rapamycin analogs with anti-inflammatories using medical devices
US8257725B2 (en) 1997-09-26 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US8257726B2 (en) 1997-09-26 2012-09-04 Abbott Laboratories Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
PT1056454E (pt) * 1998-02-23 2003-08-29 Fujisawa Pharmaceutical Co Utilizacao de compostos macrolido para o tratamento do glaucoma
AUPP223198A0 (en) * 1998-03-06 1998-04-02 Fujisawa Pharmaceutical Co., Ltd. New use
ME00189B (me) 1998-03-26 2011-02-10 Astellas Pharma Inc Preparati sa neprekidnim oslobađanjem
CA2326222C (en) * 1998-04-27 2008-09-23 Fujisawa Pharmaceutical Co., Ltd. Medicinal compositions
ES2226409T3 (es) 1998-07-17 2005-03-16 Agouron Pharmaceuticals, Inc. Compuestos, composiciones y procedimientos para estimular el crecimiento y elongacion neuronales.
US7960405B2 (en) 1998-09-24 2011-06-14 Abbott Laboratories Compounds and methods for treatment and prevention of diseases
US8257724B2 (en) 1998-09-24 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US7455853B2 (en) 1998-09-24 2008-11-25 Abbott Cardiovascular Systems Inc. Medical devices containing rapamycin analogs
MXPA01003376A (es) 1998-10-02 2002-11-07 Kosan Biosciences Inc Enzimas policetido sintetasa y construcciones de acido desoxirribonucleico recombinante para las mismas.
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
WO2000058318A1 (en) * 1999-03-31 2000-10-05 Abbott Laboratories Phosphate containing macrocyclic immunomodulators
US6121257A (en) * 1999-03-31 2000-09-19 Abbott Laboratories Sulfamate containing macrocyclic immunomodulators
US7144880B2 (en) 1999-04-30 2006-12-05 Regents Of The University Of Michigan Compositions relating to novel compounds and targets thereof
US20050113460A1 (en) * 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US20060025388A1 (en) * 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
JP5127096B2 (ja) * 1999-04-30 2013-01-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン アポトーシスにより誘導される自己免疫疾患を処置するためのベンゾジアゼピンの使用
US20040176358A1 (en) * 1999-04-30 2004-09-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US20030119029A1 (en) * 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
GB9917158D0 (en) * 1999-07-21 1999-09-22 Fujisawa Pharmaceutical Co New use
US20030018044A1 (en) * 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
US7018405B2 (en) 2000-12-22 2006-03-28 Avantec Vascular Corporation Intravascular delivery of methylprednisolone
US6471980B2 (en) 2000-12-22 2002-10-29 Avantec Vascular Corporation Intravascular delivery of mycophenolic acid
US7077859B2 (en) 2000-12-22 2006-07-18 Avantec Vascular Corporation Apparatus and methods for variably controlled substance delivery from implanted prostheses
US6939375B2 (en) 2000-12-22 2005-09-06 Avantac Vascular Corporation Apparatus and methods for controlled substance delivery from implanted prostheses
US7083642B2 (en) 2000-12-22 2006-08-01 Avantec Vascular Corporation Delivery of therapeutic capable agents
AR033151A1 (es) * 2001-04-12 2003-12-03 Sucampo Pharmaceuticals Inc Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares
US6656460B2 (en) 2001-11-01 2003-12-02 Yissum Research Development Method and composition for dry eye treatment
MXPA04007847A (es) * 2002-02-13 2005-02-24 Biogal Gyogyszergyar Metodo para extraer un macrolido de biomateria.
US7452692B2 (en) * 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter
HUE025145T2 (en) * 2002-02-22 2016-01-28 Meda Ab A method for reducing and treating immunosuppression induced by ultraviolet B radiation
AU2002321821A1 (en) * 2002-06-28 2004-01-19 Biocon Limited Solid state fermentation and fed batch for the production of an immunosuppressant
US20060171984A1 (en) 2002-09-06 2006-08-03 Cromack Keith R Device having hydration inhibitor
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
WO2004069845A1 (en) * 2003-02-10 2004-08-19 Biocon Limited Solid state fermentation and fed batch for the production of an immunosuppressant
WO2004089958A2 (en) 2003-03-31 2004-10-21 TEVA Gyógyszergyár Részvénytársaság Crystallization and purification of macrolides
US20060169199A1 (en) * 2003-03-31 2006-08-03 Vilmos Keri Crystallization and purification of macrolides
EP1641437A4 (en) * 2003-07-09 2009-06-03 Chong Kun Dang Pharm Corp SOLID DISPERSION OF TACROLIMUS
PL1558622T3 (pl) * 2003-07-24 2008-06-30 Teva Gyogyszergyar Zartkoerueen Muekoedoe Reszvenytarsasag Sposób oczyszczania makrolidów
WO2005011796A1 (ja) * 2003-08-05 2005-02-10 Kaneka Corporation 生体留置用ステント
US8591946B2 (en) 2003-08-29 2013-11-26 Veloxis Pharmaceuticals A/S Modified release compositions comprising tacrolimus
WO2005020993A1 (en) 2003-08-29 2005-03-10 Lifecycle Pharma A/S Modified release compositions comprising tacrolimus
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
CN1867664A (zh) * 2003-10-17 2006-11-22 兰贝克赛实验室有限公司 使用新的链霉菌菌种生产他克莫司(fk－506)
DE602004031356D1 (de) 2003-11-21 2011-03-24 Zalicus Inc Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
EP1697383B1 (en) * 2003-12-05 2014-04-23 Biocon Limited Process for the purification of tacrolimus
KR100485877B1 (ko) * 2003-12-30 2005-04-28 종근당바이오 주식회사 타크롤리무스를 생산하는 미생물 및 이를 이용한타크롤리무스의 대량 생산방법
US20050176080A1 (en) * 2004-02-10 2005-08-11 Vani Bodepudi Hapten, immunogens and derivatives of ascomycin useful for preparation of antibodies and immunoassays
AU2005222719B2 (en) 2004-03-19 2011-03-24 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
US8431145B2 (en) 2004-03-19 2013-04-30 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
DK1756290T3 (en) 2004-04-12 2016-08-22 Biocon Ltd Streptomyces sp. BICC 7522 AND THE USE THEREOF FOR THE PRODUCTION OF MACRO-LIDER
US20050272723A1 (en) * 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US20090275099A1 (en) * 2004-04-27 2009-11-05 Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
JP2006014722A (ja) * 2004-06-02 2006-01-19 Keio Gijuku 遺伝子マーカー及びその利用
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
WO2006080951A2 (en) * 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
US20060052369A1 (en) * 2004-09-07 2006-03-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
JP2008512125A (ja) * 2004-09-10 2008-04-24 アイバックス ファーマシューティカルズ スポレツノスト エス ルチェニム オメゼニム マクロリド化合物を単離する方法
US20080312447A1 (en) * 2004-09-10 2008-12-18 Ivax Pharmaceuticals S.R.O. Process for Isolation of Crystalline Tacrolimus
GT200500282A (es) * 2004-10-12 2006-05-04 Heteroatomos conteniendo compuestos triciclicos.
ITMI20042098A1 (it) * 2004-11-03 2005-02-03 Antibioticos Spa Processo per la purificazione di tacrolimus
CA2584430A1 (en) 2004-12-01 2006-06-08 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Methods for preparing pimecrolimus
CA2590675A1 (en) * 2004-12-15 2006-06-22 Elan Pharma International Ltd. Nanoparticulate tacrolimus formulations
CA2586692A1 (en) * 2004-12-22 2006-06-29 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Method of purifying macrolides
JP2008528448A (ja) * 2005-01-03 2008-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 新規化合物に関連する組成物および方法、ならびにその標的
JP2007527434A (ja) * 2005-01-05 2007-09-27 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ 非晶質タクロリマス及びその調製
ATE532064T1 (de) * 2005-01-13 2011-11-15 Univ Keio Genmarker und dessen verwendung
JP5242374B2 (ja) 2005-03-23 2013-07-24 アボット・ラボラトリーズ 組成物ならびに長期効力を得るための医療機器を用いたラパマイシン類縁体の投与方法
ATE533520T1 (de) 2005-03-23 2011-12-15 Abbott Lab Abgabe von stark lipophilen mitteln durch medizinprodukte
JP2008545757A (ja) 2005-06-01 2008-12-18 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 溶媒和されていないベンゾジアゼピン組成物および方法
CN1876822B (zh) * 2005-06-06 2010-05-12 上海市农药研究所 他克莫司的产生菌株及生产方法
WO2007013017A1 (en) * 2005-07-29 2007-02-01 Ranbaxy Laboratories Limited A process for purification of macrolides
ITMI20051549A1 (it) * 2005-08-05 2007-02-06 Antibioticos Spa Purificazione del tacrolimus su supporti dimorigine vegetale
WO2007029082A2 (en) * 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited An improved fermentation process for preparing ascomycin
US20080318289A1 (en) * 2005-10-05 2008-12-25 Parveen Kumar Fermentation Processes for the Preparation of Tacrolimus
US20070105844A1 (en) * 2005-10-26 2007-05-10 Regents Of The University Of Michigan Therapeutic compositions and methods
EP1948191B1 (en) 2005-11-01 2013-01-16 The Regents of the University of Michigan Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
JP2009514969A (ja) 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
US7678901B2 (en) 2006-02-28 2010-03-16 Wyeth Rapamycin analogs containing an antioxidant moiety
US7622477B2 (en) 2006-02-28 2009-11-24 Cordis Corporation Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same
US20080000834A1 (en) * 2006-03-15 2008-01-03 Ladislav Cvak Process for purifying Tacrolimus
US8022188B2 (en) * 2006-04-24 2011-09-20 Abbott Laboratories Immunosuppressant binding antibodies and methods of obtaining and using same
US7759338B2 (en) * 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
EP2418206A3 (en) 2006-06-09 2012-06-27 The Regents of the University of Michigan Benzodiazepine derivatives useful in the treatment of autoimmune disorders
JPWO2008026781A1 (ja) 2006-08-31 2010-01-21 直人 奥 逆標的化脂質小胞体
WO2008033466A2 (en) * 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
TW200837067A (en) * 2006-11-06 2008-09-16 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Ascomycin and pimecrolimus having reduced levels of desmethylascomycin and 32-deoxy-32-epichloro-desmethylascomycin respectively, and methods for preparation thereof
JP2010515753A (ja) 2007-01-10 2010-05-13 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 肺内送達用免疫抑制剤組成物の送達の増強
US10265407B2 (en) 2007-02-15 2019-04-23 Yale University Modular nanodevices for smart adaptable vaccines
US20100151436A1 (en) * 2007-03-02 2010-06-17 Fong Peter M Methods for Ex Vivo Administration of Drugs to Grafts Using Polymeric Nanoparticles
KR101164718B1 (ko) * 2007-03-09 2012-07-11 더 리젠츠 오브 더 유니버시티 오브 미시간 신규 화합물 및 이의 표적에 관한 조성물 및 방법
HUE033011T2 (hu) 2007-05-30 2017-11-28 Veloxis Pharmaceuticals As Takrolimuszt tartalmazó napi egyszeri orális dózisforma
US12083103B2 (en) 2007-05-30 2024-09-10 Veloxis Pharmaceuticals, Inc. Tacrolimus for improved treatment of transplant patients
KR100891313B1 (ko) * 2007-08-17 2009-03-31 (주) 제노텍 담체로 작용하는 흡착성 수지의 제공에 의한 트리사이클로화합물의 생산 및 추출 방법
MX2010002732A (es) 2007-09-14 2010-06-02 Univ Michigan Inhibidores de f1f0-atpasa y metodos relacionados.
CN101918375A (zh) 2007-11-06 2010-12-15 密歇根大学董事会 在皮肤病症的治疗中有用的苯并二氮杂*酮化合物
US8921642B2 (en) * 2008-01-11 2014-12-30 Massachusetts Eye And Ear Infirmary Conditional-stop dimerizable caspase transgenic animals
KR101003042B1 (ko) 2008-03-17 2010-12-21 종근당바이오 주식회사 고순도 타크로리무스의 정제 방법
MX2010011068A (es) * 2008-04-08 2010-11-04 Amyris Biotechnologies Inc Expresion de secuencias heterologas.
US12403095B2 (en) 2008-05-30 2025-09-02 Veloxis Pharmaceuticals, Inc. Stabilized tacrolimus composition
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US20100092479A1 (en) * 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
US8497307B2 (en) 2008-09-11 2013-07-30 The Regents Of The University Of Michigan Aryl guanidine F1F0-ATPase inhibitors and related methods
KR100910165B1 (ko) 2008-09-18 2009-07-30 (주) 제노텍 은 이온 용액 추출을 이용한 불포화 알킬기를 가진 락톤 화합물 정제방법
WO2010041684A1 (ja) * 2008-10-08 2010-04-15 高田製薬株式会社 タクロリムス外用剤
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
NZ593649A (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
WO2010121164A2 (en) 2009-04-17 2010-10-21 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
CN101712686B (zh) * 2009-06-22 2012-08-29 鲁南制药集团股份有限公司 一种发酵液中他克莫司的分离纯化方法
EP2272963A1 (en) * 2009-07-09 2011-01-12 LEK Pharmaceuticals d.d. Process for Preparation of Tacrolimus
EP2470020A4 (en) 2009-09-18 2013-03-13 Univ Michigan BENZODIAZEPINONE COMPOUNDS AND TREATMENT METHODS THEREWITH
JP5856064B2 (ja) 2009-11-17 2016-02-09 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 治療特性を有する１，４−ベンゾジアゼピン−２，５−ジオンおよび関連化合物
WO2011062765A2 (en) 2009-11-17 2011-05-26 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
US20110130711A1 (en) * 2009-11-19 2011-06-02 Follica, Inc. Hair growth treatment
US8480620B2 (en) 2009-12-11 2013-07-09 Abbott Cardiovascular Systems Inc. Coatings with tunable solubility profile for drug-coated balloon
US8951595B2 (en) 2009-12-11 2015-02-10 Abbott Cardiovascular Systems Inc. Coatings with tunable molecular architecture for drug-coated balloon
TWI510238B (zh) 2010-02-17 2015-12-01 Lifecycle Pharma As 穩定化他克莫司（ｔａｃｒｏｌｉｍｕｓ）組合物
SG184324A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
WO2011163600A2 (en) 2010-06-25 2011-12-29 Apt Pharmaceuticals, Inc. Tacrolimus compositions for aerosol administration
KR101261131B1 (ko) 2010-08-24 2013-05-06 이화여자대학교 산학협력단 신규 타크롤리무스 유도체, 상기 유도체를 포함하는 신경 보호용 조성물, 상기 유도체를 포함하는 면역 억제용 조성물, 상기 유도체의 생산 방법 및 상기 유도체의 생산 균주
WO2012026896A1 (en) 2010-08-25 2012-03-01 Les Laboratoires Medis Sa Surface modified micronized tacrolimus crystalline particles and pharmaceutical compositions thereof
US10117411B2 (en) 2010-10-06 2018-11-06 Dow Agrosciences Llc Maize cytoplasmic male sterility (CMS) C-type restorer RF4 gene, molecular markers and their use
TR201909840T4 (tr) 2011-03-11 2019-07-22 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antikorları ve kullanımları.
US9597385B2 (en) 2012-04-23 2017-03-21 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
KR102085557B1 (ko) 2013-03-14 2020-03-06 엘커메스 파마 아일랜드 리미티드 푸마레이트의 프로드럭 및 다양한 질환을 치료하는데 있어서의 이들의 용도
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
KR102233251B1 (ko) 2013-04-03 2021-03-26 엔-폴드 엘엘씨 신규 나노입자 조성물
WO2015073691A1 (en) 2013-11-14 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of bmp signaling
CN104650112B (zh) * 2013-11-18 2018-07-31 山东新时代药业有限公司 他克莫司8-丙基类似物的制备方法
UY35927A (es) 2013-12-31 2015-07-31 Dow Agrosciences Llc ?gen restaurador rf3 de tipo s de la esterilidad masculina citoplasmática del maíz (cms), marcadores moleculares y sus usos?.
EP3094324A4 (en) * 2014-01-13 2017-02-22 Amplyx Pharmaceuticals, Inc. Antifungal compounds
CA2935167C (en) 2014-01-16 2022-02-22 Musc Foundation For Research Development Targeted nanocarriers for the administration of immunosuppressive agents
JP6337135B2 (ja) 2014-02-24 2018-06-06 アルカーメス ファーマ アイルランド リミテッド フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用
KR101694879B1 (ko) * 2014-08-01 2017-01-12 주식회사 인트론바이오테크놀로지 면역억제활성 없이 신경재생활성이 유지되는 fk506 유도체 및 그의 용도
US10143682B2 (en) 2014-10-28 2018-12-04 Koushi Yamaguchi Medicine for improving state of pregnancy, and use thereof
US20180243224A1 (en) 2015-08-19 2018-08-30 Vivus, Inc. Pharmaceutical formulations
BR112018004296B1 (pt) 2015-09-04 2020-05-05 Primatope Therapeutics Inc anticorpos anti-cd40 humanizados e usos dos mesmos
CN106074367A (zh) * 2016-07-20 2016-11-09 中山大学中山眼科中心 含fk506类化合物/fkbp蛋白二聚体的药物组合物及其制备方法
CN108384819B (zh) * 2017-02-03 2021-06-25 上海医药工业研究院 一种用于发酵他克莫司的培养基以及发酵方法
RU2686779C1 (ru) * 2018-07-26 2019-04-30 Общество с ограниченной ответственностью "Изварино Фарма" Штамм streptomyces tsukubensis - продуцент такролимуса и способ получения такролимуса
US20210228551A1 (en) 2018-08-10 2021-07-29 Koushi Yamaguchi Therapeutic agent for humoral immunity-related diseases in maternofetal relationship
WO2020076738A2 (en) * 2018-10-12 2020-04-16 Bellicum Pharmaceuticals, Inc Protein-binding compounds
EP3930713B1 (en) 2018-12-04 2025-05-28 Ilko Ilaç Sanayi Ve Ticaret Anonim Sirketi Stable tacrolimus ointment formulation for topical treatment of skin conditions
CN120053439A (zh) 2018-12-18 2025-05-30 山口晃史 用于改善不孕不育症或妊娠状态的药物
WO2020163594A1 (en) * 2019-02-07 2020-08-13 The Regents Of The University Of California Immunophilin binding agents and uses thereof
GR1009790B (el) 2019-03-20 2020-08-03 Φαρματεν Α.Β.Ε.Ε. Σκευασμα παρατεταμενης αποδεσμευσης που περιλαμβανει τακρολιμους
WO2022187379A1 (en) 2021-03-03 2022-09-09 Sana Biotechnology, Inc. Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3244592A (en) * 1962-06-09 1966-04-05 Arai Tadashi Ascomycin and process for its production
JPS54110000A (en) * 1978-02-17 1979-08-29 Kaken Pharmaceut Co Ltd Novel streptovaricin c derivative
US4309504A (en) * 1980-01-28 1982-01-05 Eli Lilly And Company Process for preparing narasin
US4654334A (en) * 1980-10-08 1987-03-31 International Minerals & Chemical Corp. Manganese-containing antibiotic agents
US4415669A (en) * 1981-12-07 1983-11-15 Merck & Co., Inc. Substance and process for its production
US4390546A (en) * 1981-12-07 1983-06-28 Merck & Co., Inc. Antiparasitic macrolide from a strain of Streptomyces hygroscopicus
US4510317A (en) * 1983-07-28 1985-04-09 Hoffmann-La Roche Inc. Antibiotic X-14934A
GB8430455D0 (en) * 1984-12-03 1985-01-09 Fujisawa Pharmaceutical Co Fr-900506 substance
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5254562A (en) * 1984-12-03 1993-10-19 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5266692A (en) * 1984-12-03 1993-11-30 Fujisawa Pharmaceutical Co., Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
DK175235B1 (da) * 1987-11-09 2004-07-19 Novartis Ag Ny anvendelse af azatricycloderivater og farmaceutiske præparater med indhold deraf
US5956352A (en) * 1992-04-24 1999-09-21 Digital Equipment Corporation Adjustable filter for error detecting and correcting system

Also Published As

Publication number Publication date
LU90317I2 (fr) 1999-01-11
US6482845B1 (en) 2002-11-19
US6201005B1 (en) 2001-03-13
FI854731A0 (fi) 1985-11-29
DK556285A (da) 1986-06-04
FI85977B (fi) 1992-03-13
KR930010705B1 (ko) 1993-11-08
JP3211891B2 (ja) 2001-09-25
US20050124646A1 (en) 2005-06-09
US20030170831A1 (en) 2003-09-11
EP0184162A2 (en) 1986-06-11
CA1338491C (en) 1996-07-30
JPH11343294A (ja) 1999-12-14
IL77222A (en) 1991-06-10
KR930010707B1 (ko) 1993-11-08
FI85977C (fi) 1992-06-25
JPH0372483A (ja) 1991-03-27
MX9202943A (es) 1992-06-30
KR930010704B1 (ko) 1993-11-08
NO854833L (no) 1986-06-04
AU5059685A (en) 1986-06-12
NL960023I1 (nl) 1996-12-02
FI864527L (fi) 1986-11-07
IE62865B1 (en) 1995-03-08
US5830717A (en) 1998-11-03
PT81589B (pt) 1987-10-20
ATE104984T1 (de) 1994-05-15
JPH1112281A (ja) 1999-01-19
FI864527A0 (fi) 1986-11-07
IL92345A (en) 1991-06-10
JP2976966B2 (ja) 1999-11-10
GR852904B (enExample) 1986-04-01
JPH07224066A (ja) 1995-08-22
HK18596A (en) 1996-02-09
EP0184162B1 (en) 1994-04-27
US20030229115A1 (en) 2003-12-11
CN1013687B (zh) 1991-08-28
KR860004918A (ko) 1986-07-16
JPH0346445B2 (enExample) 1991-07-16
DK169550B1 (da) 1994-11-28
JPH0372484A (ja) 1991-03-27
CN85109492A (zh) 1986-06-10
NL960023I2 (nl) 1997-06-02
IE852971L (en) 1986-06-03
JPH1067783A (ja) 1998-03-10
DK556285D0 (da) 1985-11-29
ES549478A0 (es) 1987-04-16
NZ214407A (en) 1989-11-28
DE3587806D1 (de) 1994-06-01
FI87803B (fi) 1992-11-13
US6028097A (en) 2000-02-22
JPH0720970B2 (ja) 1995-03-08
US5110811A (en) 1992-05-05
FI854731L (fi) 1986-06-04
US4929611A (en) 1990-05-29
FI87803C (fi) 1993-02-25
KR930010706B1 (ko) 1993-11-08
JP2828091B2 (ja) 1998-11-25
US5565559A (en) 1996-10-15
ES8705038A1 (es) 1987-04-16
PT81589A (en) 1986-01-01
US4894366A (en) 1990-01-16
US20040029908A1 (en) 2004-02-12
JP2746134B2 (ja) 1998-04-28
US5496727A (en) 1996-03-05
NO168372B (no) 1991-11-04
KR930010708B1 (ko) 1993-11-08
HU195250B (en) 1988-04-28
CY1912A (en) 1985-11-30
DE19575026I2 (de) 2002-03-28
NO168372C (no) 1992-02-12
US4956352A (en) 1990-09-11
AU592067B2 (en) 1990-01-04
EP0184162A3 (en) 1989-02-08
HUT41842A (en) 1987-05-28
US5624842A (en) 1997-04-29

Similar Documents

Publication Publication Date Title
DE3587806T2 (de) Tricyclische Verbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzung.
EP0627009B1 (en) Macrocyclic lactones and a productive strain thereof
US5254562A (en) Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US4975372A (en) Microbial transformation product of L-683,590
US5266692A (en) Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5290772A (en) Immunosuppressant agent
US5268370A (en) Microbial transformation product of L-679,934

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
V448 Application of spc

Free format text: PRODUCT NAME: TACROLIMUS (INN); REGISTRATION NO/DATE: 30793.00.00, 30793.00.01, 30793.01.00; 19950321

Spc suppl protection certif: 195 75 026

Filing date: 19950727

V457 Spc granted

Free format text: PRODUCT NAME: TACROLIMUS (INN); REGISTRATION NO/DATE: 30793.00.00, 30793.00.01, 30793.01.00; 19950321

Spc suppl protection certif: 195 75 026

Filing date: 19950727

V464 Spc expired

Free format text: PRODUCT NAME: TACROLIMUS (INN); REGISTRATION NO/DATE: 30793.00.00, 30793.00.01, 30793.01.00; 19950321

Spc suppl protection certif: 195 75 026

Filing date: 19950727